=================================================================
This file is a part of the 1999 Hyperreal Drug Archives Snapshot.  
This snapshot is hosted by Erowid and will not be updated after 
October 1999.  The information in these files may be out of date.  
See Erowid's Psychoactive Vaults for more current info.
=================================================================

Newsgroups: alt.drugs
From: lamont@hyperreal.com (Lamont Granquist)
Subject: Medline info on drug-drug interactions
Message-ID: <1993Oct25.205133.10949@beaver.cs.washington.edu>
Date: Mon, 25 Oct 93 20:51:33 GMT

----------------------------------------------------------------------
On drug-drug interactions:

               Accession Number: 93000357.    Citation: 2 of 4

Author:         Strassman-R-J.
Title:          Human hallucinogen interactions with drugs affecting
                serotonergic neurotransmission.
Source:         Neuropsychopharmacology.  1992 Nov.  7(3).  P 241-3.
Abstract:       The absence of relevant human research studies of
                hallucinogenic drugs has not curtailed their unsupervised
                use.  Two cases are presented that suggest decreased
                sensitivity to the serotonergic hallucinogens psilocybin and
                LSD induced by drugs with effects on serotonergic
                neurotransmission, allopurinol and fluoxetine.  These reports
                suggest that hallucinogens' effects in humans are mediated by
                serotonergic receptors.

               Accession Number: 92272338.    Citation: 3 of 4

Author:         Picker-W.  Lerman-A.  Hajal-F.
Title:          Potential interaction of LSD and fluoxetine [letter]
Source:         Am-J-Psychiatry.  1992 Jun.  149(6).  P 843-4.

               Accession Number: 93359556.    Citation: 1 of 45

Author:         McCann-U-D.  Ricaurte-G-A.
Title:          Reinforcing subjective effects of (+/-)
                3,4-methylenedioxymethamphetamine ("ecstasy") may be
                separable from its neurotoxic actions: clinical evidence.
Source:         J-Clin-Psychopharmacol.  1993 Jun.  13(3).  P 214-7.
Abstract:       (+/-)3,4-Methylenedioxymethamphetamine (MDMA), a synthetic
                amphetamine derivative used recreationally by humans, damages
                brain serotonin neurons in experimental animals.  In
                preclinical studies, serotonin reuptake inhibitors block
                MDMA-induced serotonin release; they also block MDMA
                neurotoxicity.  Whether serotonin reuptake inhibitors also
                block MDMA's psychoactive effects in humans has not been
                established.  Reported herein are four individuals who
                describe their experiences after ingesting fluoxetine, a
                potent and selective serotonin reuptake inhibitor, before
                MDMA ingestion.  Their reports indicate that fluoxetine does
                not block MDMA's reinforcing subjective effects and raise the
                possibility that MDMA's psychoactive effects may be separable
                from its neurotoxic actions.